Moxifloxacin Hydrochloride
(mox'' i flox' a sin hye'' droe klor' ide).
+'&img=../../images/v35300/cas-186826-86-8.gif&casNumber=186826-86-8&usp=35&nf=30&chemicalStructureImage=true&ID='+parent.myID,600,500);)
437.89(4aS-cis)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid, monohydrochloride.
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride
[186826-86-8].» Moxifloxacin Hydrochloride contains not less than 98.0 percent and not more than 102.0 percent of C21H24FN3O4·HCl, calculated on the anhydrous basis.
Packaging and storage—
Preserve in tight, light-resistant containers. Store at room temperature.
USP Reference standards 
11
—
11—
USP Moxifloxacin Hydrochloride RS 
') + '&img=../../images/v35300/cas-186826-86-8.gif',600,500);)
USP Moxifloxacin Related Compound A RS
1-Cyclopropyl-6,8-difluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid.
C20H21F2N3O3 389.40
1-Cyclopropyl-6,8-difluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid.
C20H21F2N3O3 389.40
Identification—
B:
The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
C:
To a solution (1 in 160) add diluted nitric acid, and filter. The filtrate meets the requirements of the tests for Chloride 191.
191.
Specific rotation 781S:
between 
125
and 138 at 20.
781S:
between 125 and 138 at 20.
Test solution:
10 mg per mL, in a mixture of water and acetonitrile (1:1).
Microbial enumeration tests 61 and Tests for specified microorganisms 62—
The total aerobic microbial count does not exceed 1000 cfu per g, and the total combined molds and yeasts count does not exceed 100 cfu per g.
61 and Tests for specified microorganisms 62—
The total aerobic microbial count does not exceed 1000 cfu per g, and the total combined molds and yeasts count does not exceed 100 cfu per g.
pH 791:
between 3.9 and 4.6, in a solution (0.2 in 100).
791:
between 3.9 and 4.6, in a solution (0.2 in 100).
Water, Method Ia 921:
not more than 4.5%.
921:
not more than 4.5%.
Residue on ignition 281:
not more than 0.1%.
281:
not more than 0.1%.
Sulfate 221—
A 0.6-g portion shows no more sulfate than corresponds to 0.25 mL of 0.020 N sulfuric acid (0.04%).
221—
A 0.6-g portion shows no more sulfate than corresponds to 0.25 mL of 0.020 N sulfuric acid (0.04%).
Related compounds—
[note—Protect solutions from light. ]
Mobile phase and Diluent—
Prepare as directed in the Assay.
Blank solution—
Use the Diluent.
Resolution solution—
Prepare as directed in the Assay.
Sensitivity solution—
Dilute an accurately measured volume of the Standard solution with Diluent to obtain a solution containing about 0.05 µg per mL. [note—Store the Sensitivity solution under refrigeration and protected from light. ]
Standard solution—
Dissolve an accurately weighed quantity of USP Moxifloxacin Hydrochloride RS in Diluent, and dilute quantitatively, and stepwise if necessary, with Diluent to obtain a solution having a known concentration of about 0.002 mg per mL.
Test solution—
Use the Assay preparation.
Chromatographic system
(see Chromatography 621)—Prepare the Chromatographic system as directed in the Assay. Chromatograph the Resolution solution, and record the peak responses as directed for Procedure: the resolution, R, between moxifloxacin and moxifloxacin related compound A is not less than 1.5. Chromatograph the Standard solution, and record the peak responses as directed for Procedure: the column efficiency using the moxifloxacin peak is not less than 4000 theoretical plates; the tailing factor is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. In addition, chromatograph the Sensitivity solution, and record the peak response as directed for Procedure. Confirm that the signal-to-noise ratio of the moxifloxacin peak is not less than 10.
621)—Prepare the Chromatographic system as directed in the Assay. Chromatograph the Resolution solution, and record the peak responses as directed for Procedure: the resolution, R, between moxifloxacin and moxifloxacin related compound A is not less than 1.5. Chromatograph the Standard solution, and record the peak responses as directed for Procedure: the column efficiency using the moxifloxacin peak is not less than 4000 theoretical plates; the tailing factor is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. In addition, chromatograph the Sensitivity solution, and record the peak response as directed for Procedure. Confirm that the signal-to-noise ratio of the moxifloxacin peak is not less than 10.
Procedure—
Separately inject equal volumes (about 25 µL) of the Blank solution, the Standard solution, and the Test solution into the chromatograph, record the chromatograms for at least 2 times the retention time of moxifloxacin, and measure the peak responses, disregarding any peaks corresponding to those obtained from the Blank solution. Calculate the percentage of each impurity in the portion of Moxifloxacin Hydrochloride taken by the formula:
(CS / CU)(1/F)(100)(ri / rS)
in which CS is the concentration, in mg per mL, of USP Moxifloxacin Hydrochloride RS in the Standard solution; CU is the concentration, in mg per mL, of Moxifloxacin Hydrochloride in the Test solution; F is the relative response factor for the individual related compound; ri is the peak response of each individual impurity; rS is the peak response of moxifloxacin in the Standard solution; and 100 is the conversion factor to percentage. The limits as shown in Table 1 are met.
Table 1
| Related Compound | F | Relative Retention Time vs. Moxifloxacin |
Limit (%) |
|
|---|---|---|---|---|
| Moxifloxacin related compound A1 | 1.0 | 1.15 | 0.1 | |
| 6,8-Dimethoxy2 | 0.71 | 1.32 | 0.1 | |
| 8-Ethoxy3 | 1.0 | 1.48 | 0.1 | |
| 6-Methoxy-8-fluoro4 | 1.0 | 1.71 | 0.1 | |
| 8-Hydroxy5 | 0.29 | 1.83 | 0.1 | |
| Other individual impurity |
1.0 | — | 0.1 | |
| Total impurities | — | — | 0.5 | |
|
1
1-Cyclopropyl-6,8-difluoro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.
|
||||
|
2
1-Cyclopropyl-6,8-dimethoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.
|
||||
|
3
1-Cyclopropyl-8-ethoxy-6-fluoro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.
|
||||
|
4
1-Cyclopropyl-8-fluoro-6-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.
|
||||
|
5
1-Cyclopropyl-6-fluoro-8-hydroxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.
|
||||
Assay—
Buffer solution—
Dissolve 0.5 g of tetrabutylammonium hydrogen sulfate and 1.0 g of monobasic potassium phosphate in water, add 2 mL of phosphoric acid, dilute with water to 1000 mL, mix, and pass through a 0.45-µm filter.
Mobile phase—
Prepare a degassed mixture of Buffer solution and methanol (18:7). Make adjustments if necessary (see System Suitability under Chromatography 621).
621).
Diluent—
Add 20 mg of anhydrous sodium sulfite to 1000 mL of Buffer solution, mix gently, and pass through a 0.45-µm filter.
Resolution solution—
Dissolve suitable quantities of USP Moxifloxacin Hydrochloride RS and USP Moxifloxacin Related Compound A RS in Diluent to obtain a solution containing about 0.1 mg per mL and 0.001 mg per mL, respectively.
Standard preparation—
Dissolve an accurately weighed quantity of USP Moxifloxacin Hydrochloride RS in Diluent, and dilute quantitatively, and stepwise if necessary, with Diluent to obtain a solution having a known concentration of about 0.1 mg per mL.
Assay preparation—
Transfer about 50 mg of Moxifloxacin Hydrochloride, accurately weighed, to a 10-mL volumetric flask, dissolve in and dilute with Diluent to volume, and mix. Transfer 1.0 mL of this solution to a 50-mL volumetric flask, dilute with Diluent to volume, and mix.
Chromatographic system (see Chromatography 621)—
The liquid chromatograph is equipped with a 293-nm detector and 4.0-mm × 25-cm column that contains 5-µm packing L11. The flow rate is about 0.9 mL per minute. The column temperature is maintained at 45. Chromatograph the Resolution solution as directed for Procedure, and identify the components based on their relative retention times (about 1.0 for moxifloxacin and 1.2 for moxifloxacin related compound A). The resolution, R, between moxifloxacin and moxifloxacin related compound A is not less than 1.5. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the column efficiency using the moxifloxacin peak is not less than 4000 theoretical plates; the tailing factor is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.
621)—
The liquid chromatograph is equipped with a 293-nm detector and 4.0-mm × 25-cm column that contains 5-µm packing L11. The flow rate is about 0.9 mL per minute. The column temperature is maintained at 45. Chromatograph the Resolution solution as directed for Procedure, and identify the components based on their relative retention times (about 1.0 for moxifloxacin and 1.2 for moxifloxacin related compound A). The resolution, R, between moxifloxacin and moxifloxacin related compound A is not less than 1.5. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the column efficiency using the moxifloxacin peak is not less than 4000 theoretical plates; the tailing factor is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure—
Separately inject equal volumes (about 25 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the percentage of C21H24FN3O4·HCl in the portion of Moxifloxacin Hydrochloride taken by the formula:
100(CS / CU)(rU / rS)
in which 100 is the conversion factor to percentage; CS is the concentration, in mg per mL, of USP Moxifloxacin Hydrochloride RS in the Standard preparation; CU is the concentration, in mg per mL, of Moxifloxacin Hydrochloride in the Assay preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information—
Please check for your question in the FAQs before contacting USP.
| Topic/Question | Contact | Expert Committee |
|---|---|---|
| Monograph | Leonel M. Santos, Ph.D.
Senior Scientific Liaison 1-301-816-8168 |
(SM12010) Monographs - Small Molecules 1 |
| Reference Standards | RS Technical Services 1-301-816-8129 rstech@usp.org |
|
| 61 |
Radhakrishna S Tirumalai, Ph.D.
Principal Scientific Liaison 1-301-816-8339 |
(GCM2010) General Chapters - Microbiology |
| 62 |
Radhakrishna S Tirumalai, Ph.D.
Principal Scientific Liaison 1-301-816-8339 |
(GCM2010) General Chapters - Microbiology |
USP35–NF30 Page 3959
Pharmacopeial Forum: Volume No. 34(5) Page 1170